Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
NCT05155033Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2022
- Primary completion
- Sep 2031
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, aldesleukin in melanoma, renal cell carcinoma (RCC), sponsored by National Cancer Institute. Started Aug 2022; status: recruiting.
02
Drugs
pembrolizumabaldesleukin
03
Conditions
melanomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05155033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05155033.